Sai Samyuktha Bandaru
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sai Samyuktha Bandaru has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Deepti Kantamani
Baton Rouge General Medical Center-Bluebonnet, Internal Medicine Residency Program, Baton Rouge, LA, 70809-3679, USA
1 shared publication - Ganji Purnachandra Nagaraju
Division of Hematology and Oncology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35233, USA
1 shared publication Gantuya Tserenpil
Weiss Memorial Hospital
1 shared publication- Jennifer L. Miatech
Baton Rouge General Internal Medicine Residency Program, Baton Rouge General Medical Center, Baton Rouge, LA, USA
1 shared publication - M. Patrick Stagg
Our Lady of the Lake Regional Medical Center, Franciscan Missionaries of Our Lady Healthcare System, Baton Rouge, Louisiana
1 shared publication Mohammad Nabil Rayad
Saint Michaels Medical Center
1 shared publication
Latest Publications
- Open Access
- 16 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23207
Atypical Hemolytic Uremic Syndrome Caused by a Rare Complement Factor B Mutation
Thrombotic microangiopathy (TMA), a rare and diagnostically challenging condition, commonly presents with a triad of thrombocytopenia, hemolytic anemia, and end-organ damage, such as renal failure. Most cases of the hemolytic uremic syndrome (HUS) are mediated by Shiga toxin-producing Escherichia coli, but some cases present as an atypical HUS, which includes thrombotic thrombocytopenic purpura and complement-mediated thrombotic microangiopathy (C-TMA). Although C-TMA occurs because of genetic and acquired mutations in the complement regulatory factors, it is usually hereditary. The currently available treatment options include therapeutic plasma exchange and administration of eculizumab, which is a monoclonal antibody against C5. Here, we report a diagnostically challenging and extremely rare case of a middle-aged Caucasian man who was diagnosed with atypical HUS that was caused by a mutation in complement factor B. This case highlights the importance of not overlooking rare causes of TMAs because the diagnostic evaluation is important for guiding appropriate management and obtaining a favorable prognosis.
- 16 March 2022
- Published by Springer Nature in Cureus
- Vol. 14 (3) , e23207
Open AccessAtypical Hemolytic Uremic Syndrome Caused by a Rare Complement Factor B Mutation
Thrombotic microangiopathy (TMA), a rare and diagnostically challenging condition, commonly presents with a triad of thrombocytopenia, hemolytic anemia, and end-organ damage, such as renal failure. Most cases of the hemolytic uremic syndrome (HUS) are mediated by Shiga toxin-producing Escherichia coli, but some cases present as an atypical HUS, which includes thrombotic thrombocytopenic purpura and complement-mediated thrombotic microangiopathy (C-TMA). Although C-TMA occurs because of genetic and acquired mutations in the complement regulatory factors, it is usually hereditary. The currently available treatment options include therapeutic plasma exchange and administration of eculizumab, which is a monoclonal antibody against C5. Here, we report a diagnostically challenging and extremely rare case of a middle-aged Caucasian man who was diagnosed with atypical HUS that was caused by a mutation in complement factor B. This case highlights the importance of not overlooking rare causes of TMAs because the diagnostic evaluation is important for guiding appropriate management and obtaining a favorable prognosis.
- 1 January 2022
- Published by Begell House Inc. Publishers in Onco Therapeutics
- Vol. 9 (1) , 35-50
The Role of Phytochemicals in the Treatment of Colorectal Cancer
Colorectal cancer (CRC) is one of the leading causes of morbidity and mortality worldwide with an ever-increasing incidence rate. Commonly used treatment modalities for CRC include chemotherapy and radiotherapy, which are often associated with adverse effects and limited efficacy. Literature review indicates that multiple factors play a role in CRC pathogenesis such as genetic predispositions, alteration in the gut microbiome and dietary changes. Hence, it is important to develop a multi-targeted approach for CRC prevention and treatment. Phytochemicals are naturally occurring compounds that exhibit anti-cancer and antioxidant properties by regulating multiple pathways that are involved in CRC tumorigenesis. Numerous phytochemicals exert therapeutic effects against CRC. In this review, we have discussed the role of some widely acknowledged phytochemicals like curcumin, resveratrol, and sulforaphane in both the CRC onset and progression. These phytochemicals are naturally occurring and are known to exhibit anti-cancer activity against CRC by regulating various key signaling pathways including the Wnt/ β-catenin signaling pathway. By regulating vital molecular pathways, the course of CRC can be positively altered. The evidence outlined within this literature review suggests the significance of these phytochemicals as preventive agents and their potential role in developing effective therapies. This review emphasizes the molecular mechanisms of curcumin, resveratrol, and sulforaphane that can effectively target CRC development and progression. Additionally, previously performed in vitro and in vivo studies including these promising phytochemicals have also been briefly summarized.
- 1 January 2022
- Published by Begell House Inc. Publishers in Onco Therapeutics
- Vol. 9 (1) , 35-50
The Role of Phytochemicals in the Treatment of Colorectal Cancer
Colorectal cancer (CRC) is one of the leading causes of morbidity and mortality worldwide with an ever-increasing incidence rate. Commonly used treatment modalities for CRC include chemotherapy and radiotherapy, which are often associated with adverse effects and limited efficacy. Literature review indicates that multiple factors play a role in CRC pathogenesis such as genetic predispositions, alteration in the gut microbiome and dietary changes. Hence, it is important to develop a multi-targeted approach for CRC prevention and treatment. Phytochemicals are naturally occurring compounds that exhibit anti-cancer and antioxidant properties by regulating multiple pathways that are involved in CRC tumorigenesis. Numerous phytochemicals exert therapeutic effects against CRC. In this review, we have discussed the role of some widely acknowledged phytochemicals like curcumin, resveratrol, and sulforaphane in both the CRC onset and progression. These phytochemicals are naturally occurring and are known to exhibit anti-cancer activity against CRC by regulating various key signaling pathways including the Wnt/ β-catenin signaling pathway. By regulating vital molecular pathways, the course of CRC can be positively altered. The evidence outlined within this literature review suggests the significance of these phytochemicals as preventive agents and their potential role in developing effective therapies. This review emphasizes the molecular mechanisms of curcumin, resveratrol, and sulforaphane that can effectively target CRC development and progression. Additionally, previously performed in vitro and in vivo studies including these promising phytochemicals have also been briefly summarized.
- Open Access
- 11 October 2021
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2021, 1-4
Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.
- 11 October 2021
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2021, 1-4
Open AccessSalivary Duct Carcinoma: Case Reports and Brief Review of the Literature
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,000 patients. Standard treatment for SDC is wide surgical resection along with lymph node dissection followed by adjuvant radiation therapy. The role of adjuvant chemotherapy is not known. In this report, we present three cases of SDC. A 71-year-old female with T1N0M0 disease was treated with total parotidectomy, ipsilateral neck dissection, and adjuvant radiotherapy without evidence of disease recurrence at 5 months. The second is a 59-year-old female with TXN1M0 disease who was treated with total parotidectomy with ipsilateral level I-IV neck dissection and adjuvant radiotherapy without evidence of disease occurrence at 21 months. The third case is a 79-year-old male with widely metastatic disease, including brain metastases, treated with cranial irradiation, leuprolide, and lapatinib who remains under home hospice care.